284 related articles for article (PubMed ID: 15788682)
1. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
2. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
3. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
[TBL] [Abstract][Full Text] [Related]
4. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.
Sattler M; Pride YB; Ma P; Gramlich JL; Chu SC; Quinnan LA; Shirazian S; Liang C; Podar K; Christensen JG; Salgia R
Cancer Res; 2003 Sep; 63(17):5462-9. PubMed ID: 14500382
[TBL] [Abstract][Full Text] [Related]
5. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the Akt/mTOR pathway on EGF-induced cell transformation.
Nomura M; He Z; Koyama I; Ma WY; Miyamoto K; Dong Z
Mol Carcinog; 2003 Sep; 38(1):25-32. PubMed ID: 12949840
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
[TBL] [Abstract][Full Text] [Related]
9. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the met receptor in mesothelioma.
Mukohara T; Civiello G; Davis IJ; Taffaro ML; Christensen J; Fisher DE; Johnson BE; Jänne PA
Clin Cancer Res; 2005 Nov; 11(22):8122-30. PubMed ID: 16299245
[TBL] [Abstract][Full Text] [Related]
11. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells.
Cho Y; Park MJ; Park M; Min SS; Yee J; Kim C; Han MS; Han SH
Respirology; 2009 Aug; 14(6):850-8. PubMed ID: 19703066
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
Nozawa H; Watanabe T; Nagawa H
Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol-3 kinase/Akt/p70S6K/AP-1 signaling pathway mediated benzo(a)pyrene-induced cell cycle alternation via cell cycle regulatory proteins in human embryo lung fibroblasts.
Gao A; Liu B; Shi X; Jia X; Ye M; Jiao S; You B; Huang C
Toxicol Lett; 2007 Apr; 170(1):30-41. PubMed ID: 17383120
[TBL] [Abstract][Full Text] [Related]
16. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
20. K252a inhibits the oncogenic properties of Met, the HGF receptor.
Morotti A; Mila S; Accornero P; Tagliabue E; Ponzetto C
Oncogene; 2002 Jul; 21(32):4885-93. PubMed ID: 12118367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
